Loading...

TRDA ENTRADA THERAPEUTICS INC US FDA Inspections 8-K Filing

NTRD

TRD

ENTRADA THERAPEUTICS INC

(TRDA)

2025 8-K

Financial Results Announced

Financial Statements

Financial Statements

Workforce Reductions

Clinical Trial Authorization

Financial Results

Clinical Trial Authorization

Financial Update

Financial Results

Financial Results

Securities Purchase Agreement

Update on ENTR-601-44

Annual Meeting and Amendmen...

Financial Results Announcement

Financial Results Announcement

Management Change

Resignations and Appointments

Update on ENTR-601-44

Financial Results Announcement

Amendment to License Agreem...

Sales Agreement

Clinical Trial Announcement

Appointment of Director

Financial Results Announcement

Clinical Trial Authorization

Resignation and Annual Meeting

Financial Results Announcement

Appointment of Director

Financial Results Announcement

Strategic Collaboration and...

External Links:

Entrada Therapeutics has received authorization from the UK to start a Phase 1/2 clinical study of its drug ENTR-601-44 for treating Duchenne muscular dystrophy, expected to begin in Q2 2025.

AI Assistant

ENTRADA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.